Bitensky L, Cashman B, Johnstone J J, Chayen J
Ann Rheum Dis. 1977 Oct;36(5):448-52. doi: 10.1136/ard.36.5.448.
Human rheumatoid synovial lining cells have up to four times the capacity to oxidize glucose 6-phosphate, the first step of the hexose monophosphate pathway, as do the nonrheumatoid cells. The reducing equivalents produced by this system have many significant metabolic effects. Exposure of these cells by 10(-5) M prednisolone in vitro, or to 6 mg/day in vivo, causes some depression of this activity in the rheumatoid synovial lining cells; less than this dose of steroid, or the administration of nonsteroidal drugs in vivo, has little or no effect. The depression of activity produced by 6 mg/day does not bring this activity down to the value found in nonrheumatoid synoviocytes.
人类类风湿性滑膜衬里细胞氧化6-磷酸葡萄糖（己糖磷酸途径的第一步）的能力是非类风湿性细胞的四倍。该系统产生的还原当量具有许多重要的代谢作用。在体外，用10^(-5)M泼尼松龙处理这些细胞，或在体内给予6mg/天的剂量，会使类风湿性滑膜衬里细胞的这种活性有所降低；低于此剂量的类固醇，或在体内给予非甾体类药物，几乎没有影响。每天6mg剂量所导致的活性降低并未使该活性降至非类风湿性滑膜细胞中的值。
